These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29860043)

  • 1. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.
    Gold MH; Lebwohl M; Biesman BS; Robinson DM; Luo L; Berk DR; Ahluwalia G; Alvandi N
    J Am Acad Dermatol; 2018 Sep; 79(3):e57-e59. PubMed ID: 29860043
    [No Abstract]   [Full Text] [Related]  

  • 2. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
    Kircik LH; DuBois J; Draelos ZD; Werschler P; Grande K; Cook-Bolden FE; Weng E; Berk DR; Ahluwalia G
    J Drugs Dermatol; 2018 Jan; 17(1):97-105. PubMed ID: 29320594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
    Draelos ZD; Gold MH; Weiss RA; Baumann L; Grekin SK; Robinson DM; Kempers SE; Alvandi N; Weng E; Berk DR; Ahluwalia G
    J Am Acad Dermatol; 2018 Jun; 78(6):1156-1163. PubMed ID: 29409914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials.
    Stein-Gold L; Kircik L; Draelos ZD; Werschler P; DuBois J; Lain E; Baumann L; Goldberg D; Kaufman J; Tanghetti E; Ahluwalia G; Alvandi N; Weng E; Berk D
    J Drugs Dermatol; 2018 Nov; 17(11):1201-1208. PubMed ID: 30500142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
    Kuang AW; DuBois J; Attar M; Ahluwalia G
    J Drugs Dermatol; 2018 Feb; 17(2):213-220. PubMed ID: 29462230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxymetazoline Hydrochloride 1% Cream (Rhofade) for Persistent Facial Erythema Associated with Rosacea.
    Garcia C; Birch M
    Am Fam Physician; 2018 Jun; 97(12):808-810. PubMed ID: 30216014
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
    Patel NU; Shukla S; Zaki J; Feldman SR
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1049-1054. PubMed ID: 28837365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline.
    Shanler SD; Ondo AL
    Arch Dermatol; 2007 Nov; 143(11):1369-71. PubMed ID: 18025359
    [No Abstract]   [Full Text] [Related]  

  • 9. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
    Baumann L; Goldberg DJ; Stein Gold L; Tanghetti EA; Lain E; Kaufman J; Weng E; Berk DR; Ahluwalia G
    J Drugs Dermatol; 2018 Mar; 17(3):290-298. PubMed ID: 29537447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical Management of Facial Redness in Rosacea.
    Cline A; McGregor SP; Feldman SR
    Dermatol Clin; 2018 Apr; 36(2):151-159. PubMed ID: 29499798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
    Tanghetti EA; Dover JS; Goldberg DJ; Dhawan SS; Luo L; Berk DR; Ahluwalia G; Alvandi N
    J Drugs Dermatol; 2018 Jun; 17(6):621-626. PubMed ID: 29879249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.
    DuBois J; Dover JS; Jones TM; Weiss RA; Berk DR; Ahluwalia G
    J Drugs Dermatol; 2018 Mar; 17(3):308-316. PubMed ID: 29537449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.
    Eichenfield LF; Del Rosso JQ; Tan JKL; Hebert AA; Webster GF; Harper J; Baldwin HE; Kircik LH; Stein-Gold L; Kaoukhov A; Alvandi N
    Br J Dermatol; 2019 May; 180(5):1050-1057. PubMed ID: 30500065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Erythematotelangiectatic Rosacea With Pulsed-Dye Laser and Oxymetazoline 1.0% Cream: A Retrospective Study.
    Suggs AK; Macri A; Richmond H; Munavalli G; Friedman PM
    Lasers Surg Med; 2020 Jan; 52(1):38-43. PubMed ID: 31709571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.
    Hoover RM; Erramouspe J
    Ann Pharmacother; 2018 Mar; 52(3):263-267. PubMed ID: 29094614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
    Okwundu N; Cline A; Feldman SR
    J Dermatolog Treat; 2021 Mar; 32(2):137-143. PubMed ID: 31294643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
    Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence.
    Del Rosso JQ; Tanghetti E
    J Clin Aesthet Dermatol; 2021 Mar; 14(3):32-37. PubMed ID: 33841614
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
    Del Rosso JQ
    J Am Acad Dermatol; 2013 Dec; 69(6 Suppl 1):S44-56. PubMed ID: 24229637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythema of Rosacea: Validation of Patient's Self-Assessment Grading Scale.
    Tan J; Leoni M
    J Drugs Dermatol; 2015 Aug; 14(8):841-4. PubMed ID: 26267728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.